ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 61 filers reported holding ALIGOS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $481,000 | -41.1% | 644,553 | -23.3% | 0.00% | – |
Q2 2023 | $816,000 | +1992.3% | 840,393 | +1779.4% | 0.00% | – |
Q1 2023 | $39,000 | – | 44,715 | +248316.7% | 0.00% | – |
Q4 2022 | $0 | – | 18 | +38.5% | 0.00% | – |
Q3 2022 | $0 | – | 13 | 0.0% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 13 | -99.0% | 0.00% | – |
Q1 2022 | $3,000 | -94.2% | 1,311 | -69.9% | 0.00% | – |
Q4 2021 | $52,000 | +92.6% | 4,362 | +146.7% | 0.00% | – |
Q3 2021 | $27,000 | +3.8% | 1,768 | +37.7% | 0.00% | – |
Q2 2021 | $26,000 | +85.7% | 1,284 | +103.8% | 0.00% | – |
Q1 2021 | $14,000 | -6.7% | 630 | +16.0% | 0.00% | – |
Q4 2020 | $15,000 | – | 543 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 2,320,381 | $47,301,000 | 15.67% |
Pivotal bioVenture Partners Investment Advisor LLC | 876,548 | $17,873,000 | 7.04% |
Vivo Capital, LLC | 3,547,030 | $72,306,000 | 3.13% |
Novo Holdings A/S | 2,614,563 | $53,311,000 | 2.36% |
ACUTA CAPITAL PARTNERS, LLC | 214,254 | $4,368,000 | 1.75% |
Boxer Capital, LLC | 1,526,048 | $31,108,000 | 1.10% |
VR Adviser, LLC | 408,377 | $8,325,000 | 1.01% |
Cormorant Asset Management, LP | 905,467 | $18,458,000 | 0.63% |
HHLR ADVISORS, LTD. | 2,165,064 | $44,135,000 | 0.45% |
Logos Global Management LP | 212,785 | $4,339,000 | 0.36% |